Urology

Urology Seminar CME / CPD 

Full Course:  20 AMA PRA Category 1 Credits for CME / CEU / CPD

Short Course:  10 AMA PRA Category 1 Credits for CME / CEU / CPD

Course(s) are appropriate for:   Urologists, Family Practitioners, Pediatricians, Internists, General Practitioners, Nurses, Nurse Practitioners, Physician Assistants (PA-C's)

Series 42 (URO42) Topics Include:  Treatment for Male Infertility, Radical Cystectomy, Evaluating Emerging Genomic Tests, Dietary Interventions for Prostate Cancer, Urinary Dysfunction, and more.

To view topic outline of the full or short course, select the Course Type (Full or Short) below:

Full Course:
URO42
Full Course Price:
$580
Short Course:
URO42A, URO42B
Short Course Price:
$485
Format:
Available in Audio format.

Course Topics

Men's Urology

Evaluate the efficacy of cosmetic procedures of the male genitalia; Choose treatment options for patients with Peyronie disease; Diagnose causes of infertility in men; Plan appropriate treatment of men with infertility; Formulate a treatment algorithm for patients with chronic orchialgia.

Highlights in Prostate Cancer

Critically evaluate emerging genomic tests that assess risk in patients with prostate cancer; Outline the findings of a survey of physicians that assessed the use of the cell cycle progression score to evaluate patients with prostate cancer; Explain the purported interaction between statins and androgen deprivation therapy; Interpret the findings of the SWOG S9346 study; Define androgen annihilation

Transgender Patients, Oncofertility, and Sexual Health

List the criteria for performing gender-affirming surgery; Outline strategies for the treatment of patients with gender dysphoria; Provide counseling about infertility to male patients undergoing cancer therapy; Evaluate patients with erectile dysfunction after cancer treatment; Consider options for the treatment of sexual dysfunction after treatment for cancer.

Prostate Cancer in Practical Urology

Compare sexual and urinary function in patients who undergo radical prostatectomy, radiation therapy, or active surveillance; Elaborate on the role of androgen deprivation therapy as an adjunct to radiation therapy in patients with recurrent prostate cancer; Optimize the use of adjuvant radiation therapy in patients with prostate cancer; Evaluate the role of radical prostatectomy and lymphadenectomy in patients with locally advanced prostate cancer; Provide patients with options for treatment of asymptomatic and symptomatic castration-resistant metastatic prostate cancer

Review of Bladder Cancer

Weigh the advantages and disadvantages of ultrasonography and computed tomography urography in the evaluation of patients with microscopic hematuria; Recognize the variant subtypes of bladder cancer and their clinical implications; Select patients with bladder cancer who are most likely to benefit from therapy using targeted agents; Implement effective strategies for follow-up of patients after radical cystectomy; Identify risk factors and treatment options for late complications of radical cystectomy.

Highlights from the 22nd Annual Scottsdale Prostate Cancer Symposium

Explain the major findings of the ProtecT study; Manage active surveillance for low-risk prostate cancer; Characterize the risks and benefits of transrectal ultrasound-guided biopsy of the prostate; List risk factors for infection in men undergoing biopsy of the prostate; Counsel a patient asking about dietary interventions for prostate cancer.

Management of Carcinoma and Radical Cystectomy

Distinguish low-risk from high-risk upper tract urothelial carcinoma; Compare endoscopic treatment with nephroureterectomy in the treatment of patients with upper tract urothelial carcinoma; Choose among pathologic tests to guide treatment for patients with renal cell carcinoma; Implement preoperative measures to optimize recovery of patients undergoing radical cystectomy; Prevent readmission of patients undergoing radical cystectomy.

Bladder Outlet Obstruction/Urodynamics in Women

Diagnose and treat patients with neurogenic bladder; Recognize urinary dysfunction characteristic of patients with Parkinson disease and Shy-Drager syndrome; Identify patterns of urinary dysfunction in patients who have undergone radical pelvic surgery; Select appropriate urodynamic studies for patients with urinary dysfunction; Use the 9 Cs to interpret the findings of a urodynamic study.

Update on Bladder and Kidney Cancers

Weigh the benefits and risks of trimodal therapy and radical cystectomy in patients with muscle-invasive bladder cancer; Implement strategies to improve local control of disease in patients with muscle-invasive bladder cancer; Summarize the recommended treatment for patients with T1a renal masses; Optimize the use of ablation and active surveillance in patients with renal masses; Evaluate the efficacy of immunotherapy and adjuvant therapy in the treatment of patients with kidney cancer.

Prostate Cancer: Genomics/Radiation

Recognize the limitations of pathologic analysis for stratifying risk in men with prostate cancer; Select patients with prostate cancer for whom genomic testing is indicated; Compare the roles of magnetic resonance imaging and genomic testing in men with prostate cancer; Review the research on optimal dosing of I125 seed implants and compare the effects of dose in low- and high-risk patients. Identify factors that increase the risk for urinary and rectal side effects of brachytherapy.

Men's Urology

Evaluate the efficacy of cosmetic procedures of the male genitalia; Choose treatment options for patients with Peyronie disease; Diagnose causes of infertility in men; Plan appropriate treatment of men with infertility; Formulate a treatment algorithm for patients with chronic orchialgia.

Transgender Patients, Oncofertility, and Sexual Health

List the criteria for performing gender-affirming surgery; Outline strategies for the treatment of patients with gender dysphoria; Provide counseling about infertility to male patients undergoing cancer therapy; Evaluate patients with erectile dysfunction after cancer treatment; Consider options for the treatment of sexual dysfunction after treatment for cancer.

Review of Bladder Cancer

Weigh the advantages and disadvantages of ultrasonography and computed tomography urography in the evaluation of patients with microscopic hematuria; Recognize the variant subtypes of bladder cancer and their clinical implications; Select patients with bladder cancer who are most likely to benefit from therapy using targeted agents; Implement effective strategies for follow-up of patients after radical cystectomy; Identify risk factors and treatment options for late complications of radical cystectomy.

Management of Carcinoma and Radical Cystectomy

Distinguish low-risk from high-risk upper tract urothelial carcinoma; Compare endoscopic treatment with nephroureterectomy in the treatment of patients with upper tract urothelial carcinoma; Choose among pathologic tests to guide treatment for patients with renal cell carcinoma; Implement preoperative measures to optimize recovery of patients undergoing radical cystectomy; Prevent readmission of patients undergoing radical cystectomy.

Update on Bladder and Kidney Cancers

Weigh the benefits and risks of trimodal therapy and radical cystectomy in patients with muscle-invasive bladder cancer; Implement strategies to improve local control of disease in patients with muscle-invasive bladder cancer; Summarize the recommended treatment for patients with T1a renal masses; Optimize the use of ablation and active surveillance in patients with renal masses; Evaluate the efficacy of immunotherapy and adjuvant therapy in the treatment of patients with kidney cancer.

Highlights in Prostate Cancer

Critically evaluate emerging genomic tests that assess risk in patients with prostate cancer; Outline the findings of a survey of physicians that assessed the use of the cell cycle progression score to evaluate patients with prostate cancer; Explain the purported interaction between statins and androgen deprivation therapy; Interpret the findings of the SWOG S9346 study; Define androgen annihilation

Prostate Cancer in Practical Urology

Compare sexual and urinary function in patients who undergo radical prostatectomy, radiation therapy, or active surveillance; Elaborate on the role of androgen deprivation therapy as an adjunct to radiation therapy in patients with recurrent prostate cancer; Optimize the use of adjuvant radiation therapy in patients with prostate cancer; Evaluate the role of radical prostatectomy and lymphadenectomy in patients with locally advanced prostate cancer; Provide patients with options for treatment of asymptomatic and symptomatic castration-resistant metastatic prostate cancer

Highlights from the 22nd Annual Scottsdale Prostate Cancer Symposium

Explain the major findings of the ProtecT study; Manage active surveillance for low-risk prostate cancer; Characterize the risks and benefits of transrectal ultrasound-guided biopsy of the prostate; List risk factors for infection in men undergoing biopsy of the prostate; Counsel a patient asking about dietary interventions for prostate cancer.

Bladder Outlet Obstruction/Urodynamics in Women

Diagnose and treat patients with neurogenic bladder; Recognize urinary dysfunction characteristic of patients with Parkinson disease and Shy-Drager syndrome; Identify patterns of urinary dysfunction in patients who have undergone radical pelvic surgery; Select appropriate urodynamic studies for patients with urinary dysfunction; Use the 9 Cs to interpret the findings of a urodynamic study.

Prostate Cancer: Genomics/Radiation

Recognize the limitations of pathologic analysis for stratifying risk in men with prostate cancer; Select patients with prostate cancer for whom genomic testing is indicated; Compare the roles of magnetic resonance imaging and genomic testing in men with prostate cancer; Review the research on optimal dosing of I125 seed implants and compare the effects of dose in low- and high-risk patients. Identify factors that increase the risk for urinary and rectal side effects of brachytherapy.

Additional Information

Additional Continuing Medical Education options available:

Other courses of interest may include:  PediatricsFamily PracticeInternal Medicine, DiabetesObesity and Nutrition.

If you have taken the current Urology CME / CPD Review listed above or if you are seeking additional credits, please visit: Medical Courses Coming Soon There you will find abbreviated listings of additional courses available related to this specialty and courses that are soon to be released.

For over 30 years, ASI has provided Continuing Medical Education, CME & CEU and Continuing Professional Development Education (CPD) for physicians and allied professionals in Urology plus over 40 other specialties and subspecialties.  Lectures are recorded annually at the top seminars and conferences to provide the most current medical education to our clients.

Testimonials

  • Excellent diversity of speakers and subjects.

    William M., MD, Tennessee